SCHEMBL16645174

SCHEMBL16645174

CC(C)(O)CS(=O)(=O)Nc1ccc2c(c1)CCN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.61
ESR2 Q92731 1/20 0.58
NR1H2 P55055 1/20 0.52
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PTPN1 P18031 4/20 0.44
JAK2 O60674 2/20 0.42
JAK3 P52333 2/20 0.42
PTK2 Q05397 2/20 0.42
MAPT P10636 1/20 0.41
IGF1R P08069 1/20 0.41
ABHD6 Q9BV23 1/20 0.41
HDAC1 Q13547 1/20 0.41
KCNA1 Q09470 2/20 0.40
KCNAB1 Q14722 2/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
PTPN2 P17706 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29728602 1.00 NAMPT (0.61) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL16634693 0.87 NAMPT (0.62) NAMPTESR2PTPN1KCNA1KCNAB1
SCHEMBL4789781 0.87 ESR2 (0.66) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL16645110 0.86 ESR2 (0.56) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL29728634 0.86 ESR2 (0.56) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL16645224 0.86 ESR2 (0.56) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL29728647 0.85 ESR2 (0.53) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL16645145 0.85 ESR2 (0.53) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL16645109 0.85 ESR2 (0.55) NAMPTESR2NR1H2NPC1RAB9A
SCHEMBL5600152 0.82 NR1H2 (0.65) NAMPTESR2NR1H2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT NAMPT 1/4885ESR2 4495/4885NR1H2 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.